Inhibikase Therapeutics Inc (NQ: IKT )
1.270
+0.040
(+3.25%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 16, 2024
Add to My Watchlist
All News about Inhibikase Therapeutics Inc
![](https://investorplace.com/wp-content/uploads/2019/09/pills-1.jpg)
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/01/24/image20.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/roce_image_4272.jpeg?width=1200&height=800&fit=crop)
Looking Into Inhibikase Therapeutics's Return On Capital Employed
December 27, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_6661.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_6576.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/01/25/image31.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/07/image44.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/07/image17.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_29702.jpeg?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022
November 16, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/08/29/image29.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/16/image41.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/15/image22.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/08/26/bz-pharma_4.jpg?width=1200&height=800&fit=crop)
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
August 26, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/11/08/image16.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/08/26/bz-pharma_1.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/07/image14.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_8422.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_8408.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/08/30/image-bed_bath__beyond.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/ep_us_feature_image_4572.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/08/29/image42.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/06/15/premkt_movers.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/08/16/image16.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/08/15/image31.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/roce_image_899.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2012/cells-gdd37bc5d2_1920_20.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_3199.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/ep_us_feature_image_1819.jpeg?width=1200&height=800&fit=crop)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.